Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Fig. 4

Effects of CUDC-907 and olaparib on DNA damage. a DNA damage detected by comet assay in SCLC cells upon treatment with 10 nM CUDC-907 or 10 μM olaparib alone and in combination for 48 h. Scale bar, 60 μm. DNA in the tail was used to measure DNA damage and assessed by CASP software (CaspLab). Quantification of the amount of DNA damage was presented mean ± S.D. b Representative images of immunofluorescent staining for γH2AX and quantification in SCLC cells treated with indicated drugs for 24 h, Scale bar, 20 μm

Back to article page